🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

24 results for “goserelin” Clear

  1. APALUTAMIDE , RELUGOLIX , DAROLUTAMIDE , LEUPRORELIN , GOSERELIN , DEGARELIX , ENZALUTAMIDE , TRIPTORELIN , ABIRATERONE

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

  2. DEGARELIX, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, DEGARELIX, DEGARELIX, TRIPTORELIN , DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    very high risk localized or locally advanced prostate cancer

    phase 3 small molecule active

    1 trial

  3. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  4. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis Ophthalmics Europe

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  5. IBRANCE 75 mg film-coated tablets, GOSERELIN ACETATE, Placebo to match camizestrant, Placebo to match anastrozole, camizestrant, ABEMACICLIB, Placebo to match letrozole, IBRANCE 100 mg film-coated tablets, Arimidex® 1 mg Filmtabletten, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, LETROZOLE, LEUPRORELIN ACETATE, ABEMACICLIB, Camizestrant, ABEMACICLIB

    AstraZeneca AB

    Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  6. LETROZOLE, Arimidex® 1 mg Filmtabletten, Camizestrant, ABEMACICLIB, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, Nolvadex® 20 mg Filmtabletten, EXEMESTANE

    AstraZeneca AB

    ER+/HER2- Early Breast Cancer

    phase 3 small molecule active

    1 trial

  7. LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  8. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Cancer Prevention Pharma (Ireland) Limited

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  9. LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, ANASTROZOLE, GOSERELIN, LETROZOLE, GOSERELIN, EXEMESTANE, RIBOCICLIB

    Novartis Ophthalmics Europe

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  10. Locametz 25 micrograms kit for radiopharmaceutical preparation, ABIRATERONE , LEUPRORELIN , HISTRELIN , ENZALUTAMIDE , TRIPTORELIN , NILUTAMIDE , Pluvicto 1 000 MBq/mL solution for injection/infusion, GOSERELIN , DEGARELIX , BICALUTAMIDE , BUSERELIN , -, RELUGOLIX , APALUTAMIDE , DAROLUTAMIDE , FLUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  11. PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL

    Cancer Prevention Pharma (Ireland) Limited

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  12. Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE

    Olema Pharmaceuticals

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  13. TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, LEUPRORELIN, GOSERELIN, EXEMESTANE, VENLAFAXINE

    Rein Therapeutics

    Breast cancer

    phase 3 small molecule active

    1 trial

  14. ALPELISIB, FULVESTRANT, ALPELISIB, LETROZOLE, LEUPRORELIN ACETATE, GOSERELIN

    Novartis Ophthalmics Europe

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  15. BAY 1841788, DEGARELIX , LEUPRORELIN , TRIPTORELIN , GOSERELIN , TRIPTORELIN PAMOATE

    Cancer Prevention Pharma (Ireland) Limited

    Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  16. CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN

    Novartis Ophthalmics Europe

    Breast Cancer

    phase 2 small molecule active

    1 trial

  17. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Ophthalmics Europe

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  18. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Ophthalmics Europe

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  19. Leuprolide or goserelin

    NORTHWEST BIOTHERAPEUTICS INC

    Cancer

    phase 2 small molecule completed

    1 trial

  20. TRIPTORELIN, GONAPEPTYL 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée en seringues pré-remplies., LEUPRORELIN ACETATE, BAY 1841788, TRIPTORELIN, DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, DEGARELIX, LEUPRORELIN ACETATE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  21. LETROZOLE, RIBOCICLIB, GOSERELIN ACETATE, LEE011, TAMOXIFEN

    Novartis Ophthalmics Europe

    HR+, HER2- advanced or metastatic breast cancer

    approved small molecule active

    1 trial

  22. Goserelin

    First Tracks Biotherapeutics

    Allogeneic Haematopoietic Stem Cell Transplantation

    small molecule active

    1 trial

  23. Goserelin 3.6 mg implant

    INTEGRATED BIOPHARMA INC

    Postpartum Depression

    small molecule completed

    1 trial

  24. goserelin acetate

    United Therapeutics Europe Ltd

    Breast Cancer

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources